189 related articles for article (PubMed ID: 4442544)
1. Hypersensitivity to lysergic acid diethylamide (LSD-25) and psilocybin in essential headache.
Fanciullacci M; Franchi G; Sicuteri F
Experientia; 1974 Dec; 30(12):1441-3. PubMed ID: 4442544
[No Abstract] [Full Text] [Related]
2. On travels in the universe of the soul: reports on self-experiments with delysid (LSD) and psilocybin (CY).
Gelpke R
J Psychoactive Drugs; 1981; 13(1):81-9. PubMed ID: 7024496
[No Abstract] [Full Text] [Related]
3. Inhibitory effects of lysergic acid derivatives and reserpine on 5-HT binding to nerve ending particles.
Marchbanks RM
Biochem Pharmacol; 1967 Oct; 16(10):1971-9. PubMed ID: 6065963
[No Abstract] [Full Text] [Related]
4. 5-hydroxytryptamine supersensitivity as a new theory of headache and central pain: a clinical pharmacological approach with p-chlorophenylalanine.
Sicuteri F; Anselmi B; Del Bianco PL
Psychopharmacologia; 1973; 29(4):347-56. PubMed ID: 4267603
[No Abstract] [Full Text] [Related]
5. Possible involvement of the central dopaminergic system in the antireserpine effect of LSD.
Menon MK; Clark WG; Masuoka DT
Psychopharmacology (Berl); 1977 May; 52(3):291-7. PubMed ID: 406633
[No Abstract] [Full Text] [Related]
6. Lysergic acid diethylamide (LSD-25). 38. Comparison with action of methysergide and psilocybin on test subjects.
Abramson HA; Rolo A
J Asthma Res; 1965 Sep; 3(1):81-96. PubMed ID: 5318626
[No Abstract] [Full Text] [Related]
7. Reversal learning enhanced by lysergic acid diethylamide (LSD): concomitant rise in brain 5-hydroxytryptamine levels.
King AR; Martin IL; Melville KA
Br J Pharmacol; 1974 Nov; 52(3):419-26. PubMed ID: 4458849
[TBL] [Abstract][Full Text] [Related]
8. Addressing the Current Knowledge and Gaps in Research Surrounding Lysergic Acid Diethylamide (LSD), Psilocybin, and Psilocin in Rodent Models.
Ezeaka UC; Kim HJJ; Laprairie RB
Curr Top Med Chem; 2023; 23(23):2232-2241. PubMed ID: 37409550
[TBL] [Abstract][Full Text] [Related]
9. Illicit use of LSD or psilocybin, but not MDMA or nonpsychedelic drugs, is associated with mystical experiences in a dose-dependent manner.
Lyvers M; Meester M
J Psychoactive Drugs; 2012; 44(5):410-7. PubMed ID: 23457892
[TBL] [Abstract][Full Text] [Related]
10. Lysergic acid diethylamide (LSD) administration selectively downregulates serotonin2 receptors in rat brain.
Buckholtz NS; Zhou DF; Freedman DX; Potter WZ
Neuropsychopharmacology; 1990 Apr; 3(2):137-48. PubMed ID: 1969270
[TBL] [Abstract][Full Text] [Related]
11. [Effect of psilocybin on the behavior of normal mice & waltzing mice; comparison with lysergic acid monoethylamide & diethylamide].
DELAY J; THUILLIER J; NAKAJIMA H; DURANDIN MC
C R Seances Soc Biol Fil; 1959; 153(2):244-8. PubMed ID: 13663414
[No Abstract] [Full Text] [Related]
12. Response of cluster headache to psilocybin and LSD.
Sewell RA; Halpern JH; Pope HG
Neurology; 2006 Jun; 66(12):1920-2. PubMed ID: 16801660
[TBL] [Abstract][Full Text] [Related]
13. Brain serotonin metabolism after tolerance dosage of LSD.
Freedman DX; Boggan WO
Adv Biochem Psychopharmacol; 1974; 10():151-7. PubMed ID: 4846536
[No Abstract] [Full Text] [Related]
14. The possible role of tryptamine in brain function and its relationship to the actions of LSD-like hallucinogens.
Martin WR; Sloan JW
Mt Sinai J Med; 1974; 41(2):276-82. PubMed ID: 4544624
[No Abstract] [Full Text] [Related]
15. [Experimental psychosis after administration of benactyzine].
Vojtĕchovský M; Vítek V; Rysánek K
Arzneimittelforschung; 1966 Feb; 16(2):240-2. PubMed ID: 4862402
[No Abstract] [Full Text] [Related]
16. d-Lysergic acid diethylamide, psilocybin, and other classic hallucinogens: Mechanism of action and potential therapeutic applications in mood disorders.
De Gregorio D; Enns JP; Nuñez NA; Posa L; Gobbi G
Prog Brain Res; 2018; 242():69-96. PubMed ID: 30471683
[TBL] [Abstract][Full Text] [Related]
17. The biochemical pharmacology of abused drugs. I. Amphetamines, cocaine, and LSD.
Caldwell J; Sever PS
Clin Pharmacol Ther; 1974 Oct; 16(4):625-38. PubMed ID: 4607666
[No Abstract] [Full Text] [Related]
18. Mutagenicity testing of 3 hallucinogens: LSD, psilocybin and delta 9-THC, using the micronucleus test.
Van Went GF
Experientia; 1978 Mar; 34(3):324-5. PubMed ID: 631257
[TBL] [Abstract][Full Text] [Related]
19. Effect of Psilocybin, LSD, and mescaline on small, involuntary eye movements.
Hebbard FW; Fischer R
Psychopharmacologia; 1966; 9(2):146-56. PubMed ID: 5983913
[No Abstract] [Full Text] [Related]
20. Hypothesis: migraine, a central biochemical dysnociception.
Sicuteri F
Headache; 1976 Sep; 16(4):145-59. PubMed ID: 184065
[No Abstract] [Full Text] [Related]
[Next] [New Search]
